Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are currently lacking. To address this, we analysed outcomes of patients with severe treatment-refractor...
Saved in:
| Main Authors: | Tineke Kraaij, Cees van Kooten, Y K Onno Teng, Tom Huizinga, Eline J Arends, Robbert J Goekoop, Ton Rabelink, Mieke van Schaik, Marjolein J A L Wetzels, Stéphanie H Verbruggen, Sandra W van der Kooij, Sylvia W A Kamerling |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-02-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/12/1/e001424.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Remission and Reduction of Circulating Nephritic Factors by Combining Rituximab With Belimumab in a Case of Complement Factor 3 Glomerulopathy
by: Mieke van Schaik, et al.
Published: (2024-06-01) -
Measuring plasma C4D to monitor immune complexes in lupus nephritis
by: Tineke Kraaij, et al.
Published: (2019-12-01) -
Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
by: Tom W J Huizinga, et al.
Published: (2019-06-01) -
Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Patients
by: Jolijn R. van Leeuwen, et al.
Published: (2025-04-01) -
Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study
by: Karen H. Costenbader, et al.
Published: (2025-06-01)